issues

September 2013

Download PDF

COVER

SPECIAL FEATURE – Hand Held Devices: New Technologies Right the Wrongs of Earlier Devices

Contributor Cindy H. Dubin highlights in this annual report that new devices are coming to market that not only address the trends of home care and a need for delivering larger doses, but are also cleaning up the spotty reputation of early stage devices.

FEATURES

SPECIAL FEATURE – Hand Held Devices: New Technologies Right the Wrongs of Earlier Devices

Contributor Cindy H. Dubin highlights in this annual report that new devices are coming to market that not only address the trends of home care and a need for delivering larger doses, but are also cleaning up the spotty reputation of early stage devices.

THERAPEUTIC FOCUS – New Therapeutics for Aggressive Brain Cancers

Jeffrey Bacha, MBA, says glioblastoma is one of the most common and fatal brain cancers, and new therapies to treat this disease are urgently needed. New approaches, such as vaccines and immunotherapies, have promising results, and to be most effective, will need to be used in combination with a chemotherapeutic.

ADVANCED DELIVERY DEVICES – Nanocomposites for Drug Delivery Catheters

Lawrence Acquarulo, PhD, indicates an increased availability of certain medical materials could create a new wave in the development of precision devices to reach smaller areas deeper within the body.

BUSINESS DEVELOPMENT – The 5 Whys

John A. Bermingham says one of the key business success factors he has followed throughout the years is that of always trying to determine the root cause of any problem.

EXECUTIVE INTERVIEW – Capsugel DFS: Integrating Technology for Innovative Finished Dosage Forms

Drug Development Executive: Amit Patel, President of Capsugel’s Dosage Form Solutions business unit, speaks about the formulation challenges facing the industry and the increasing pressure on companies to remain competitive in today’s dynamic marketplace.

EXCIPIENT UPDATE – Maximizing the Stability of Therapeutic Proteins Using Recombinant Human Albumin

Mark Perkins, PhD, reviews some of the important factors involved, and highlights the advantages of including recombinant human albumin to stabilize protein therapeutics with reference to a recent case study.

BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part I of III

In the past two columns, The Second Quadrant focused on excipients and the roles they play in the quest to overcome bioavailability challenges of poorly soluble drugs. For the next..

EXECUTIVE INTERVIEW – Vetter: Successfully Bridging the Innovation Gap in Drug Development & Manufacturing

BIOGRAPHY Claudia Roth, PhD President, Vetter Development Service Chicago “We are noticing that CDMOs are acting more and more as the interface between small biotech firms and large drug manufacturers...

TOPICAL TRENDS – Trends in Skin Medication Dispensing

Stefan Hellbardt, PhD, and Degenhard Marx, PhD, focus their review on the trends in topical skin medication, the impact on primary packaging, and possible dispensing solutions.

Share This